Article
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Leukemia - 1 Feb 2011
Waanders E, van der Velden V H J, van der Schoot C E, van Leeuwen F N, van Reijmersdal S V, de Haas V, Veerman A J, van Kessel A Geurts, Hoogerbrugge P M, Kuiper R P, van Dongen J J M
Abstract excerpt
Response to therapy as determined by minimal residual disease (MRD) is currently used for stratification in treatment protocols for pediatric acute lymphoblastic leukemia (ALL). However, the large MRD-based medium risk group (MRD-M; 50-60% of the patients) harbors many relapses. We analyzed MRD i...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.